The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.
A novel antimicrobial susceptibility testing platform, ATB Finder, is designed to improve treatment outcomes by evaluating antibiotics under conditions that closely mirror the infection site and microbial communities found in patients. George Tetz, MD, PhD, offers insights on this platform.
Incoming SIDP President Lisa Dumkow, PharmD, FIDP, BCIDP, highlighted plans to expand mentorship, strengthen research collaboration, and move the organization's initiatives forward. She also offered insights into the new combined MAD-ID/SIDP meeting.
At the MAD-ID and SIDP 2026 annual meeting, Zachary Nelson, PharmD, MPH, BCIDP, discussed how urine-specific breakpoints can improve treatment decisions for urinary tract infections by accounting for drug concentrations in the urinary tract rather than relying solely on traditional blood-level interpretations.
Emily Heil, PharmD, MS, FIDP, BCIDP, AAHIVP, discussed the growing prevalence of metallo-β-lactamase–producing organisms in the United States and highlighted emerging therapeutic strategies designed to overcome increasingly complex antimicrobial resistance mechanisms.
Preclinical in vitro and animal models remain essential for establishing antibiotic pharmacokinetic and pharmacodynamic targets, but experts say translating those findings into real-world patient care requires careful consideration of host factors, tissue penetration, and clinical context.
Leaders from SIDP and MAD-ID highlighted their new partnership and announced the launch of the Antimicrobials meeting in 2027, focused on combining cutting-edge science with clinical antimicrobial practice.
Meera Mehta, PharmD, says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and quality-of-life considerations.
SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, explains how the new partnership between SIDP and MAD-ID brings together organizations with shared leadership and values to create a more accessible, collaborative meeting space for infectious diseases pharmacists and related specialties.
David Ha, PharmD, offers insights on how to build out a successful practice-based research project, including developing a strong research question, understanding IRB requirements early, and leveraging reliable institutional data sources and collaborations.
Systemic antibiotic therapy often leads to significant long-term disruptions to the gut microbiome. In addition to antibiotic stewardship, use of prebiotic fiber, fermented foods, and probiotics is a recommended strategy to minimize microbiome disruption and reestablish a healthy, diverse gut microbial population.
The inaugural MAD-ID and SIDP 2026 meeting aims to provide new infectious diseases education offerings, dynamic speakers, and strong networking opportunities for younger clinicians. SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, offers some insights around the upcoming event.
Emerging preclinical, compassionate-use, and randomized trial data suggest phage-antibiotic combinations may benefit select patients with multidrug-resistant infections, yet critical gaps in standardization and evidence remain.
Candida auris is a highly drug-resistant, hospital-acquired fungal pathogen. With limited treatment options, here is an overview of some of the next-generation antifungals as well as combination therapeutics.
PBPs are more than static β lactam targets. Host conditions rewire PBP activity and peptidoglycan architecture, shaping tolerance, resistance, and how we design salvage regimens.
In the midst of many changes surrounding aminoglycosides over the past several years, clinicians may be left wondering if these agents still have a role in modern clinical practice. This article summarizes changes impacting aminoglycosides, discusses where these agents may still have a role in the context of gram-negative infections, and explores future areas of study.
Climate-driven changes and other drivers of the expanding geographic range of Ixodes ticks and Lyme disease are explored.
WikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.
The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.
Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.
Obesity significantly impacts the pharmacokinetics (PK) of antifungal drugs like echinocandins, including volume of distribution (Vd) and clearance. However, despite these PK differences, current clinical evidence generally does not support the need for universal dose adjustments in obese patients. Clinicians should consider personalized dosing based on patient characteristics, infection severity, and specific drug properties due to echinocandins' favorable safety profiles.
In the third installment of our series on injectables, long-acting injectables offer new treatment and prevention options for HIV, especially benefiting patients who struggle with daily oral medications.
In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.
Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.
In the latest Bench to Bedside column, clinicians provide information and resources on recommended topics learners should explore.
PEN-FAST is a validated risk stratification tool that promotes efficient, safe, and effective de-labeling of penicillin allergies.
Management of this condition has been associated with antibiotic misuse. In the latest Bench to Bedside column, clinicians offer insights on therapy indications and what the latest literature reports on the condition.
Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).
Two RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.
In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
